Advagene Biopharma Co., Ltd. (TPEX:6709)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
31.75
+0.15 (0.47%)
At close: Feb 11, 2026
Market Cap1.89B +54.5%
Revenue (ttm)n/a
Net Income-71.10M
EPS-1.23
Shares Out59.38M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume20,922
Average Volume136,053
Open31.90
Previous Close31.60
Day's Range31.10 - 31.95
52-Week Range15.75 - 41.00
Beta0.78
RSI55.70
Earnings DateMar 20, 2026

About Advagene Biopharma

Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. It engages in the development of nasal spray influenza vaccine; respiratory allergy treatment vaccine, including rhinitis and asthma; COVID-19 immunotherapy; and other vaccines. The company was founded in 2006 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 12
Stock Exchange Taipei Exchange
Ticker Symbol 6709
Full Company Profile

Financial Performance

Financial Statements